insightful discussion of the manuscript; and to Dr Loretta Nielsen(Amylin Pharmaceuticals, Inc.) for writing the manuscript.Financial Disclosure: This research was supported by AmylinPharmaceuticals, Inc., San Diego, CA. All the authors areemployees of Amylin Pharmaceuticals, Inc., and own companystock. References 1. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin- 4 (exenatide) signiﬁcantly reduces postprandial and fastingplasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082–3089. 2. Fineman MS, Bicsak TA, Shen LZ, et al.E f f e c to ng l y c e m i c control of synthetic exendin-4 (AC-2993) additive to existingmetformin and/or sulfonylurea treatment in patients with type 2diabetes. Diabetes Care 2003; 26: 2370–2377. 3. Nielsen LL, Baron AD. Pharmaco logy of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Invest Drugs 2003; 4: 401–405. 4. Nielsen LL, Young AA, Parkes D. Pharmacology of exenatide